Biotech Values

[walldiver]

Yes, it's ironic and sad. The other factor in play here is that patients in either arm are allowed to receive Taxotere or other taxanes during the three-year followup period. For the 9901 trial, patients in the placebo arm received Taxotere at a 33% higher rate than patients in the Provenge arm. The taxane numbers for 9902A have not yet been released. Also, all-cause mortality figures have not yet been released for either trial...perhaps awaiting journal publication.